The U.S. Supreme Court has turned away Eli Lilly's appeal in a dispute over the company's patent on the cancer drug Gemzar, leaving intact a lower-court ruling that opened the door to generic competition. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments